MX2019000849A - Gel intestinal de levodopa y carbidopa y metodos de uso. - Google Patents
Gel intestinal de levodopa y carbidopa y metodos de uso.Info
- Publication number
- MX2019000849A MX2019000849A MX2019000849A MX2019000849A MX2019000849A MX 2019000849 A MX2019000849 A MX 2019000849A MX 2019000849 A MX2019000849 A MX 2019000849A MX 2019000849 A MX2019000849 A MX 2019000849A MX 2019000849 A MX2019000849 A MX 2019000849A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- levodopa
- intestinal gel
- carbidopa
- carbidopa intestinal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662364770P | 2016-07-20 | 2016-07-20 | |
| PCT/US2017/043103 WO2018017850A1 (en) | 2016-07-20 | 2017-07-20 | Levodopa and carbidopa intestinal gel and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000849A true MX2019000849A (es) | 2019-09-13 |
Family
ID=59506369
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000849A MX2019000849A (es) | 2016-07-20 | 2017-07-20 | Gel intestinal de levodopa y carbidopa y metodos de uso. |
| MX2022014577A MX2022014577A (es) | 2016-07-20 | 2019-01-18 | Gel intestinal de levodopa y carbidopa y metodos de uso. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014577A MX2022014577A (es) | 2016-07-20 | 2019-01-18 | Gel intestinal de levodopa y carbidopa y metodos de uso. |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20180021280A1 (https=) |
| EP (1) | EP3487479A1 (https=) |
| JP (3) | JP2019523249A (https=) |
| CN (1) | CN109715139A (https=) |
| AU (2) | AU2017299710A1 (https=) |
| BR (1) | BR112019001082A2 (https=) |
| CA (1) | CA3031254A1 (https=) |
| MX (2) | MX2019000849A (https=) |
| WO (1) | WO2018017850A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016258179B2 (en) | 2015-05-06 | 2021-07-01 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| US11844860B2 (en) | 2018-03-02 | 2023-12-19 | Chiesi Farmaceutici S.P.A. | Pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa |
| WO2021039084A1 (ja) * | 2019-08-30 | 2021-03-04 | テルモ株式会社 | 注射液製剤 |
| EP4616878A1 (en) * | 2024-03-15 | 2025-09-17 | Cosmo Technologies Ltd. | Cannula for rectal administration of an enema and compositions for use therewith |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5831210B2 (ja) * | 1973-04-09 | 1983-07-05 | 武田薬品工業株式会社 | アンテイナスイセイケンダクエキノセイゾウホウ |
| SE9203594D0 (sv) * | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| US6071523A (en) * | 1998-06-03 | 2000-06-06 | Taro Pharmaceuticals Industries, Ltd. | Spill resistant pharmaceutical compositions in semi-solid form |
| CN1901881A (zh) * | 2003-10-31 | 2007-01-24 | 阿尔扎公司 | 用于增强的吸收的组合物和剂型 |
| RU2484815C2 (ru) * | 2006-05-31 | 2013-06-20 | Зольвай Фармасьютиклз Гмбх | Продолжительное 24-часовое введение в кишечник леводопа/карбидопа |
| DE102006034346B4 (de) * | 2006-07-25 | 2008-11-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren und Vorrichtung zum periodischen Messen der Fließgrenze von Dispersionen sowie deren Verwendung |
| US20150182688A1 (en) * | 2013-12-31 | 2015-07-02 | Abbvie Inc. | Devices and methods for delivering a beneficial agent to a user |
| SE538425C2 (en) * | 2014-09-04 | 2016-06-21 | Lobsor Pharmaceuticals Ab | Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof |
| PT3782617T (pt) * | 2014-09-04 | 2024-02-29 | Lobsor Pharmaceuticals Ab | Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona |
| MA41377A (fr) * | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
-
2017
- 2017-07-20 WO PCT/US2017/043103 patent/WO2018017850A1/en not_active Ceased
- 2017-07-20 JP JP2019502047A patent/JP2019523249A/ja active Pending
- 2017-07-20 AU AU2017299710A patent/AU2017299710A1/en not_active Abandoned
- 2017-07-20 CA CA3031254A patent/CA3031254A1/en not_active Abandoned
- 2017-07-20 MX MX2019000849A patent/MX2019000849A/es unknown
- 2017-07-20 CN CN201780056836.5A patent/CN109715139A/zh active Pending
- 2017-07-20 EP EP17746596.0A patent/EP3487479A1/en active Pending
- 2017-07-20 BR BR112019001082-3A patent/BR112019001082A2/pt not_active Application Discontinuation
- 2017-07-20 US US15/655,078 patent/US20180021280A1/en not_active Abandoned
-
2019
- 2019-01-18 MX MX2022014577A patent/MX2022014577A/es unknown
-
2020
- 2020-04-21 US US16/854,079 patent/US20210059968A1/en not_active Abandoned
-
2022
- 2022-08-03 US US17/817,191 patent/US20230129413A1/en not_active Abandoned
- 2022-08-18 JP JP2022130386A patent/JP2022166217A/ja not_active Ceased
-
2023
- 2023-05-29 AU AU2023203340A patent/AU2023203340A1/en not_active Abandoned
-
2024
- 2024-10-02 JP JP2024173125A patent/JP2025000924A/ja active Pending
-
2025
- 2025-09-19 US US19/334,420 patent/US20260014108A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018017850A1 (en) | 2018-01-25 |
| EP3487479A1 (en) | 2019-05-29 |
| JP2019523249A (ja) | 2019-08-22 |
| JP2022166217A (ja) | 2022-11-01 |
| AU2017299710A1 (en) | 2019-01-31 |
| US20180021280A1 (en) | 2018-01-25 |
| JP2025000924A (ja) | 2025-01-07 |
| US20230129413A1 (en) | 2023-04-27 |
| BR112019001082A2 (pt) | 2019-04-30 |
| US20260014108A1 (en) | 2026-01-15 |
| CA3031254A1 (en) | 2018-01-25 |
| US20210059968A1 (en) | 2021-03-04 |
| MX2022014577A (es) | 2023-01-11 |
| CN109715139A (zh) | 2019-05-03 |
| AU2023203340A1 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX381069B (es) | Profármacos de carbidopa y l-dopa y métodos de uso. | |
| CO2019006291A2 (es) | Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas | |
| CL2020000220A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
| ECSP19043725A (es) | Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares | |
| BR112017017448A2 (pt) | métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| CL2016000950A1 (es) | Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2. | |
| MX2022014577A (es) | Gel intestinal de levodopa y carbidopa y metodos de uso. | |
| MX2017009325A (es) | Gel intestinal de levodopa y carbidopa y metodos de uso. | |
| CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| MX2018004616A (es) | Cosmetica qie tiene bacterias probioticas. | |
| EP4674433A3 (en) | Pulsatile drug delivery system for treating morning akinesia | |
| MX386055B (es) | Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| CL2020000221A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
| MX2018000021A (es) | Composiciones multifasicas. | |
| BR112018014723A2 (pt) | fantasmas bacterianos para o tratamento de câncer | |
| MX2016011025A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| MX2018002298A (es) | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. | |
| CL2019003288A1 (es) | Una combinación farmacéutica para el tratamiento de un cáncer. | |
| AR106313A1 (es) | Combinación de levodopa deuterada con carbidopa y opicapona para el tratamiento de enfermedad de parkinson | |
| CL2010001594A1 (es) | Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida. | |
| MX2019009909A (es) | Composiciones farmaceuticas para terapia de combinacion. | |
| AR103636A1 (es) | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol | |
| AR103448A1 (es) | Gel intestinal de levodopa y carbidopa y métodos de uso |